Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 16/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21156283 | 0.88 | DYRK1A (0.54) | DYRK1AGAAMAPT | |
| SCHEMBL21155867 | 0.88 | DYRK1A (0.53) | DYRK1A | |
| SCHEMBL21156272 | 0.84 | DYRK1A (0.58) | DYRK1ATHRB | |
| SCHEMBL21156810 | 0.81 | DYRK1A (0.58) | DYRK1A | |
| SCHEMBL21155873 | 0.81 | DYRK1A (0.54) | DYRK1A | |
| SCHEMBL21155880 | 0.80 | DYRK1A (0.48) | DYRK1A | |
| SCHEMBL25577209 | 0.80 | DYRK1A (0.48) | DYRK1A | |
| SCHEMBL21155872 | 0.79 | DYRK1A (0.57) | DYRK1AGRIA1CACNG8 | |
| SCHEMBL21155884 | 0.77 | DYRK1A (0.50) | DYRK1A | |
| SCHEMBL21155877 | 0.77 | DYRK1A (0.47) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-10-17 | — | — | US | disclosed |
| EP-3717475-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210032601-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-04 | — | — | US | disclosed |
| US-20200306257-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2020-10-01 | — | — | US | disclosed |
| WO-2019136320-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306257-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | MAP3K20, MAP3K1, PACSIN2 | DYRK1A 464/4885GAA 1046/4885MAPT 1065/4885 |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | MAP3K20, MAP3K1, PACSIN2 | DYRK1A 464/4885GAA 1046/4885MAPT 1065/4885 |
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | IAPP, GLP1R, GPR119 | DYRK1A 5/4885GAA 1619/4885MAPT 4231/4885 |
| US-20210032601-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | IAPP, GLP1R, GPR119 | DYRK1A 5/4885GAA 1619/4885MAPT 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.